Yao Zhi-Hong, Qin Zi-Fei, Cheng Hong, Wu Xiao-Meng, Dai Yi, Wang Xin-Luan, Qin Ling, Ye Wen-Cai, Yao Xin-Sheng
College of Pharmacy, Jinan University, Guangzhou 510632, China.
Guangdong Provincial Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China.
Molecules. 2017 Jun 2;22(6):927. doi: 10.3390/molecules22060927.
Xian-Ling-Gu-Bao capsule (XLGB), a famous traditional Chinese medicine prescription, is extensively used for the treatment of osteoporosis in China. However, few studies on the holistic quality control of XLGB have been reported. In this study, a reliable method using 18 representative components in XLGB was successfully established and applied to evaluate 34 batches of XLGB samples by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF-MS). The choice of quantitative markers mostly followed four principles, i.e., absorbed components in plasma, bioactive compounds with in vitro anti-osteoporosis activity, those derived from multiple individual medicinal herbs in XLGB with multiple representative structure types, and quantitative chemical markers in the Chinese Pharmacopoeia. The results showed chemical consistency was good except for individual batches. Multivariate statistical analysis indicated that asperosaponin VI from Radix Dipsaci, epimedin C, magnoflorine, and icariin from Herba Epimedii as well as timosaponin BII from Rhizoma Anemarrhenae varied significantly in multiple samples, which hinted an assay for these four components should be completed during all of the manufacturing processes. Taken together, this study provided a feasible method for holistic quality control of XLGB by multiple chemical markers, which could play a vital role in guaranteeing the safety, effectiveness, and controllability of administering the capsules as a medication in clinics.
仙灵骨葆胶囊(XLGB)是一种著名的中药方剂,在中国被广泛用于治疗骨质疏松症。然而,关于仙灵骨葆胶囊整体质量控制的研究报道较少。在本研究中,成功建立了一种利用仙灵骨葆胶囊中18种代表性成分的可靠方法,并通过超高效液相色谱-四极杆飞行时间质谱联用技术(UPLC/Q-TOF-MS)应用于评价34批次的仙灵骨葆胶囊样品。定量标志物的选择主要遵循四个原则,即血浆中吸收的成分、具有体外抗骨质疏松活性的生物活性化合物、来自仙灵骨葆胶囊中多种具有多种代表性结构类型的单味药材的成分以及《中国药典》中的定量化学标志物。结果表明,除个别批次外,化学一致性良好。多变量统计分析表明,续断中的川续断皂苷VI、淫羊藿中的朝藿定C、木兰花碱、淫羊藿苷以及知母中的知母皂苷BII在多个样品中差异显著,这提示在所有生产过程中都应对这四种成分进行含量测定。综上所述,本研究为仙灵骨葆胶囊通过多种化学标志物进行整体质量控制提供了一种可行的方法,这对于保证该胶囊在临床用药时的安全性、有效性和可控性具有至关重要的作用。